Advertisement
Nanobiotix S.A. (NBTX)
NASDAQ: NBTX
· Real-Time Price · USD
3.17
-0.02 (-0.63%)
At close: Apr 29, 2025, 3:05 PM
Company Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer.
Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
The company was incorporated in 2003 and is headquartered in Paris, France.
Nanobiotix S.A.
| Country | FR |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Laurent Levy Ph.D. |
Advertisement
Contact Details
Address: 60 rue de Wattignies Paris, FR | |
| Website | https://www.nanobiotix.com |
Stock Details
| Ticker Symbol | NBTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001760854 |
| CUSIP Number | 63009J107 |
| ISIN Number | US63009J1079 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Laurent Levy Ph.D. | Co-Founder, President of the Executive Board & Chief Executive Officer |
| Anne-Juliette Hermant M.A. | Chief People Officer & Member of Executive Board |
| Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board |
| Brandon Owens | Vice President of Strategic Marketing & Corporate Communication |
| Craig West CFA | Senior Vice President of Investor Relations |
| Dr. Leonard A. Farber M.D. | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board |
| Dr. Louis Kayitalire M.D. | Chief Medical Officer & Member of Executive Board |
| Earl J. Bergey Ph.d. | Co-Founder |
| Margaret Galluzzi | Vice President & Global Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | SCHEDULE 13G | Filing |
| Apr 14, 2025 | 6-K | Filing |
| Apr 14, 2025 | 6-K | Filing |
| Apr 10, 2025 | 6-K | Filing |
| Apr 02, 2025 | 20-F | Filing |
| Apr 02, 2025 | 6-K | Filing |
| Mar 31, 2025 | 6-K | Filing |
| Mar 27, 2025 | 6-K | Filing |
| Mar 20, 2025 | 6-K | Filing |
| Mar 17, 2025 | 6-K | Filing |